We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Eidogen-Sertanty, Inc. has announced that they have established collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of small molecules for anti-inflammatory indications.

Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of synthetically tractable and drug-like compounds with predicted activity against a target of interest to Kalypsys.

The collaboration builds upon Kalypsys’ existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).

"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys’ small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.

"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.